<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723447</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00053363</org_study_id>
    <nct_id>NCT03723447</nct_id>
  </id_info>
  <brief_title>Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)</brief_title>
  <acronym>TINGLE</acronym>
  <official_title>A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally, opioids are heavily utilized in treating postoperative pain but they are&#xD;
      associated with numerous side effects. The use of the transversus abdominis plane (TAP)&#xD;
      blocks have become standard practice to extend the post-operative analgesic window and limit&#xD;
      opioid use. A new liposomal-depo formulation of bupivacaine (Exparel) has gained popularity&#xD;
      as a long-lasting TAP block medication, but has not been studied in a well-powered clinical&#xD;
      trial specifically in colorectal patients nor compared to a bupivacaine/steroid mixture which&#xD;
      may offer similar effects. We conduct a prospective randomized prospective randomized study&#xD;
      of patients undergoing major laparoscopic colorectal surgery to compare the analgesic effects&#xD;
      of a bupivacaine/steroid mixture versus liposomal bupivacaine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain can pose significant challenges in the postoperative recovery of patients&#xD;
      undergoing major colorectal surgery. Traditionally, opioids have played an important role in&#xD;
      treating postoperative pain. It is well established that opioids are highly effective in&#xD;
      relieving pain; however, opioids are associated with numerous side effects that include&#xD;
      nausea, vomiting, constipation, ileus, bladder dysfunction, respiratory depression, pruritus,&#xD;
      drowsiness, sedation, and allergic reaction. These opioid side effects, which range in&#xD;
      severity, can significantly interfere with discharge home, particularly following colorectal&#xD;
      surgery. Significant interest has grown for the use of guided regional anesthesia,&#xD;
      specifically the use of the transversus abdominis plane (TAP) block to extend the&#xD;
      post-operative analgesic window and ultimately limit opioid use. While bupivacaine&#xD;
      formulations including a steroid has been shown to prolong the anesthetic effects of the&#xD;
      regional field block, a new liposomal-depo formulation of bupivacaine (Exparel) has gained&#xD;
      popularity and has additionally been shown to provide extended analgesia. Although promising&#xD;
      data exists surrounding each modality, liposomal bupivacaine has not been studied in a&#xD;
      well-powered clinical trial specifically in colorectal patients nor compared to a&#xD;
      bupivacaine/steroid mixture.&#xD;
&#xD;
      We are proposing a prospective randomized study of patients undergoing major laparoscopic&#xD;
      colorectal surgery to compare the analgesic effects of a bupivacaine/steroid mixture versus&#xD;
      liposomal bupivacaine (Exparel). We hypothesize that the liposomal formulation of bupivacaine&#xD;
      will provide superior perioperative pain control at 48 hours post-operation measured by total&#xD;
      consumed oral morphine equivalents. In addition, we will measure postoperative pain scores,&#xD;
      time until ambulation, antiemetic use, length of postoperative hospital stay, postoperative&#xD;
      ileus, and adverse events directly related or unrelated to TAP block in the 30-day&#xD;
      postoperative period between the three groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Actual">October 29, 2019</completion_date>
  <primary_completion_date type="Actual">October 29, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent)</measure>
    <time_frame>48-hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-op Pain Score (Visual Analog Scale)</measure>
    <time_frame>72-hours post-surgery</time_frame>
    <description>Visual pain scale recordings will be totaled and averaged during the first 72-hours post-surgery. Visual analog scale is determined by nursing staff when assessing pain scores. Scores range from 0-10 with 10 being the most pain. These values are typically interpreted by nursing staff as mild, moderate, or severe pain and pain medication is given accordingly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Motility</measure>
    <time_frame>72 hours post-surgery</time_frame>
    <description>Time till first bowel movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Length of Stay</measure>
    <time_frame>30 days post-surgery</time_frame>
    <description>Time from operation until hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>30 days post-surgery</time_frame>
    <description>Medical or surgical complications measured by Clavien-Dindo classification&#xD;
Clavien-Dindo grade I: any deviation from normal postoperative course&#xD;
no pharmacological or surgical treatment, endoscopic, or radiological interventions were required. Acceptable therapeutic regiments are drugs such as anti-emetics, antipyretics, analgesics, diuretics, and electrolytes. Wound infections or small abscess requiring incision at bedside is within this category&#xD;
Clavien-Dindo grade II: Normal course altered&#xD;
Pharacological management other than in grade 1. Blood transfusions and total parenteral nutrition are also included.&#xD;
Clavien-Dindo grade III: complications that require intervention of various degrees&#xD;
management of these complications require an intervention under local anesthesia or general or epidural anesthesia&#xD;
Clavien-Dindo grade IV: complications threatening the life of a patient&#xD;
manifesting in organ dysfunction, including dialysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Crohn Disease</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Gastrointestinal Disease</condition>
  <condition>Digestive System Disease</condition>
  <condition>Pain</condition>
  <condition>Pain, Neuropathic</condition>
  <condition>Intestinal Disease</condition>
  <arm_group>
    <arm_group_label>Bupivacaine/epinephrine/dexamethasone TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
    <arm_group_label>Liposomal bupivacaine TAP block</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine/epinephrine/dexamethasone</intervention_name>
    <description>Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
    <arm_group_label>Bupivacaine/epinephrine/dexamethasone TAP block</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female&#xD;
&#xD;
          2. Undergoing major laparoscopic colorectal procedure&#xD;
&#xD;
          3. Willingness and ability to sign an informed consent document&#xD;
&#xD;
          4. No allergies to anesthetic or analgesic medications&#xD;
&#xD;
          5. ASA physical status Class I - III&#xD;
&#xD;
          6. Aged 18-90 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to participate in the study&#xD;
&#xD;
          2. Age &lt;18 or &gt; 90 years&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Contraindications to regional anesthetic including but not limited to:&#xD;
&#xD;
               1. Patient refusal to regional field blockade&#xD;
&#xD;
               2. Allergy&#xD;
&#xD;
               3. Infection at the site of needle insertion&#xD;
&#xD;
               4. Systemic infection&#xD;
&#xD;
               5. Bleeding diathesis or coagulopathy (as diagnosed by history or laboratory&#xD;
                  evaluation)&#xD;
&#xD;
               6. Liver or renal disease (SCr &gt; 1.5)&#xD;
&#xD;
          5. Chronic opioid use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Zaghiyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mujukian A, Truong A, Tran H, Shane R, Fleshner P, Zaghiyan K. A Standardized Multimodal Analgesia Protocol Reduces Perioperative Opioid Use in Minimally Invasive Colorectal Surgery. J Gastrointest Surg. 2020 Oct;24(10):2286-2294. doi: 10.1007/s11605-019-04385-9. Epub 2019 Sep 12.</citation>
    <PMID>31515761</PMID>
  </reference>
  <reference>
    <citation>Truong A, Mujukian A, Fleshner P, Zaghiyan K. No Pain, More Gain: Reduced Postoperative Opioid Consumption with a Standardized Opioid-Sparing Multimodal Analgesia Protocol in Opioid-Tolerant Patients Undergoing Colorectal Surgery. Am Surg. 2019 Oct 1;85(10):1155-1158.</citation>
    <PMID>31657314</PMID>
  </reference>
  <reference>
    <citation>Knudson RA, Dunlavy PW, Franko J, Raman SR, Kraemer SR. Effectiveness of Liposomal Bupivacaine in Colorectal Surgery: A Pragmatic Nonsponsored Prospective Randomized Double Blinded Trial in a Community Hospital. Dis Colon Rectum. 2016 Sep;59(9):862-9. doi: 10.1097/DCR.0000000000000648.</citation>
    <PMID>27505115</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <results_first_submitted>December 16, 2020</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Karen Zaghiyan</investigator_full_name>
    <investigator_title>Surgeon Investigator</investigator_title>
  </responsible_party>
  <keyword>transversus abdominis plane block</keyword>
  <keyword>tap block</keyword>
  <keyword>liposomal bupivacaine</keyword>
  <keyword>exparel</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>colorectal surgery</keyword>
  <keyword>regional anesthesia</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>surgery</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03723447/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient was noted to have chronic opioid use discovered after randomization. They were subsequently excluded from analysis</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
          <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
        </group>
        <group group_id="P2">
          <title>Liposomal Bupivacaine TAP Block</title>
          <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
          <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
        </group>
        <group group_id="B2">
          <title>Liposomal Bupivacaine TAP Block</title>
          <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="29" upper_limit="67"/>
                    <measurement group_id="B2" value="42" lower_limit="29" upper_limit="57"/>
                    <measurement group_id="B3" value="42" lower_limit="29" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent)</title>
        <time_frame>48-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
            <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Liposomal Bupivacaine TAP Block</title>
            <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent)</title>
          <units>Oral morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="18" upper_limit="112"/>
                    <measurement group_id="O2" value="69" lower_limit="20" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-op Pain Score (Visual Analog Scale)</title>
        <description>Visual pain scale recordings will be totaled and averaged during the first 72-hours post-surgery. Visual analog scale is determined by nursing staff when assessing pain scores. Scores range from 0-10 with 10 being the most pain. These values are typically interpreted by nursing staff as mild, moderate, or severe pain and pain medication is given accordingly.</description>
        <time_frame>72-hours post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
            <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Liposomal Bupivacaine TAP Block</title>
            <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-op Pain Score (Visual Analog Scale)</title>
          <description>Visual pain scale recordings will be totaled and averaged during the first 72-hours post-surgery. Visual analog scale is determined by nursing staff when assessing pain scores. Scores range from 0-10 with 10 being the most pain. These values are typically interpreted by nursing staff as mild, moderate, or severe pain and pain medication is given accordingly.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Motility</title>
        <description>Time till first bowel movement</description>
        <time_frame>72 hours post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
            <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Liposomal Bupivacaine TAP Block</title>
            <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Motility</title>
          <description>Time till first bowel movement</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Length of Stay</title>
        <description>Time from operation until hospital discharge</description>
        <time_frame>30 days post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
            <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Liposomal Bupivacaine TAP Block</title>
            <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Length of Stay</title>
          <description>Time from operation until hospital discharge</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Complications</title>
        <description>Medical or surgical complications measured by Clavien-Dindo classification&#xD;
Clavien-Dindo grade I: any deviation from normal postoperative course&#xD;
no pharmacological or surgical treatment, endoscopic, or radiological interventions were required. Acceptable therapeutic regiments are drugs such as anti-emetics, antipyretics, analgesics, diuretics, and electrolytes. Wound infections or small abscess requiring incision at bedside is within this category&#xD;
Clavien-Dindo grade II: Normal course altered&#xD;
Pharacological management other than in grade 1. Blood transfusions and total parenteral nutrition are also included.&#xD;
Clavien-Dindo grade III: complications that require intervention of various degrees&#xD;
management of these complications require an intervention under local anesthesia or general or epidural anesthesia&#xD;
Clavien-Dindo grade IV: complications threatening the life of a patient&#xD;
manifesting in organ dysfunction, including dialysis</description>
        <time_frame>30 days post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
            <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Liposomal Bupivacaine TAP Block</title>
            <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Complications</title>
          <description>Medical or surgical complications measured by Clavien-Dindo classification&#xD;
Clavien-Dindo grade I: any deviation from normal postoperative course&#xD;
no pharmacological or surgical treatment, endoscopic, or radiological interventions were required. Acceptable therapeutic regiments are drugs such as anti-emetics, antipyretics, analgesics, diuretics, and electrolytes. Wound infections or small abscess requiring incision at bedside is within this category&#xD;
Clavien-Dindo grade II: Normal course altered&#xD;
Pharacological management other than in grade 1. Blood transfusions and total parenteral nutrition are also included.&#xD;
Clavien-Dindo grade III: complications that require intervention of various degrees&#xD;
management of these complications require an intervention under local anesthesia or general or epidural anesthesia&#xD;
Clavien-Dindo grade IV: complications threatening the life of a patient&#xD;
manifesting in organ dysfunction, including dialysis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clavien-Dindo grade I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clavien-Dindo grade II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clavien-Dindo grade III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for each patient for a maximum period of 3 months postoperatively.</time_frame>
      <desc>Adverse events are defined by complications or unexpected sequelae as a result of TAP block administration</desc>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine/Epinephrine/Dexamethasone TAP Block</title>
          <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.&#xD;
Bupivacaine/epinephrine/dexamethasone: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
        </group>
        <group group_id="E2">
          <title>Liposomal Bupivacaine TAP Block</title>
          <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.&#xD;
Liposomal bupivacaine: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Karen Zaghiyan</name_or_title>
      <organization>Cedars-Sinai</organization>
      <phone>(310) 289-9224</phone>
      <email>kzaghiyan@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

